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Candida glabrata can attach to various medical implants and forms thick biofilms despite its 52 
inability to switch from-yeast-to hyphae. Current in vivo C. glabrata biofilm models only 53 
provide limited information about colonization and infection and usually require animal 54 
sacrifice. To gain real-time information from individual BALB/c mice we developed a non-55 
invasive imaging technique to visualize C. glabrata biofilms in catheter fragments that were 56 
subcutaneously implanted on the back of mice. Bioluminescent C. glabrata reporter strains 57 
(lucOPT 7/2/4 and lucOPT 8/1/4), free of auxotrophic markers, expressing a codon-optimized 58 
firefly luciferase were generated. A murine subcutaneous model was used to follow real-time 59 
in vivo biofilm formation in the presence and absence of fluconazole and caspofungin. 60 
Fungal load in biofilms was quantified by colony forming unit counts and by 61 
bioluminescence imaging (BLI). C. glabrata biofilms formed within the first 24 h, as 62 
documented by the increased number of device-associated cells and elevated bioluminescent 63 
signal compared to adhesion at the time of implant. The in vivo model allowed monitoring of 64 
the anti-biofilm activity of caspofungin against C. glabrata biofilms through bioluminescent 65 
imaging from day four after initiation of treatment. Contrarily, signals emitted from biofilms 66 
implanted in fluconazole-treated mice was similar to the light emitted from control-treated 67 
mice.  68 
This study gives insights into real-time development of C. glabrata biofilms under in vivo 69 
conditions. BLI proved to be a dynamic, non-invasive and sensitive tool to monitor 70 
continuous biofilm formation and activity of antifungal agents against C. glabrata biofilms 71 





Candida glabrata is an emerging human fungal pathogen causing mucosal and deep tissue 77 
infections especially in elderly patients with a compromised immune system. Following 78 
Candida albicans, C. glabrata is the second most common isolated species from hospitalized 79 
patients in Europe (1). Although C. glabrata does not possess the ability to form true hyphae 80 
or secrete proteases, it still maintains many virulence factors, including biofilm forming 81 
capacity, which contribute to its potential to cause disease (2). The majority of life-82 
threatening infections are associated with biofilm formation on biotic and abiotic substrates. 83 
Biofilms provide microorganisms with a shelter from external effects of therapeutics, giving 84 
them an opportunity to withstand very high concentrations of antifungal agents, for example 85 
azoles (3, 4). Because of biofilm resilience to antifungals, therapeutic approaches are very 86 
limited, often leading to surgical removal of the implant material and its subsequent 87 
replacement as sole solution. Recently, our group demonstrated that in vivo C. glabrata 88 
biofilms formed inside polyurethane catheter pieces implanted subcutaneously on the back of 89 
Sprague Dawley rats (5). Biofilms were composed of multilayer structures of yeast cells 90 
embedded in extracellular matrix exhibiting increased tolerance to therapeutic concentration 91 
of fluconazole. Echinocandins proved to remain active against in vivo C. glabrata biofilm-92 
forming cells in this particular model (5). One disadvantage of almost all existing biofilm 93 
models is that the fungal load is traditionally analyzed post mortem, requiring host sacrifice. 94 
To avoid this, sensitive non-invasive techniques, such as bioluminescence imaging (BLI), 95 
provide new and often unexpected temporal and spatial information on infection development 96 
in individual animals in real time (6, 7). The monitoring of light emitted from luciferase-97 
expressing reporter cells has been used to examine an extensive range of biomolecular 98 
functions (8). BLI has been successfully applied to monitor the development of oral 99 
candidiasis (6, 9) and C. albicans dissemination after tail vein injection in mice (10-12). This 100 
technique was also employed to follow superficial and subcutaneous infections caused by C. 101 
albicans (12). Moreover, it was employed to study the time-dependent development of C. 102 
albicans biofilm formation in a subcutaneous biofilm mouse model (13). 103 
In this study, we present the construction of an auxotrophic marker-free bioluminescent C. 104 
glabrata reporter strain based on a C. glabrata-optimized firefly luciferase integrated into the 105 
HIS1 locus using HIS1 as selectable marker. This allowed us to study biofilm development in 106 
real-time by use of BLI in a mouse subcutaneous model system. It furthermore allowed us to 107 
monitor efficacy of fluconazole and caspofungin treatment in vivo and can thereby contribute 108 
to implementation of the 3Rs (replacement, reduction and refinement of animal testing) in 109 




In vitro characterization of bioluminescent strains  114 
C. glabrata reporter strains lucOPT 7/2/4 and lucOPT 8/1/4 were generated via integration of a 115 
C. glabrata-optimized firefly luciferase into the HIS1 locus using HIS1 as selectable marker. 116 
To ensure that C. glabrata lucOPT 7/2/4 and lucOPT 8/1/4 produced substantial 117 
bioluminescence and that luciferase expression did not affect growth rates, transformants 118 
were tested in series of in vitro experiments. We did not observe any changes in growth rates 119 
between reporter strains and WT in RPMI 1640, pH 7.0 and YPD medium at 37 °C (Figure 120 
S1). Additionally, we prepared 10-fold dilution series of WT and bioluminescent strains to 121 
detect the signal. Signals from reporter strains correlated (Spearman r=0.993, n=24, 122 
p<0.0001) well with the number of cells with a detection limit of about 100 cells per well 123 
(Figure S1). 124 
 125 
In vitro Candida glabrata adhesion and biofilm formation monitored by BLI  126 
To evaluate the potential use of BLI in vitro to study fungal adhesion (90 min after 127 
inoculation) and biofilm formation (after 2 days), we inoculated C. glabrata strains on the 128 
serum-coated bottom of 96-well polystyrene plates, which represents a very simple biofilm 129 
system. The bioluminescent signal acquired from the reporter strains was significantly higher 130 
compared to the WT (Figure 1A, C). A parallel XTT assay showed a significant increase in 131 
metabolic activity for all biofilm-forming cells after 2 days (Figure 1B). The BLI signal 132 
intensity from biofilms formed by luciferase-expressing strains on polyurethane catheters 133 
increased significantly compared to the signal determined from the WT strain (Figure 1D, F). 134 
The number of cfu was significantly higher during biofilm formation in comparison to 135 
adhesion (Figure 1E), which is in agreement with the BLI signal measurements. To determine 136 
whether BLI can accurately measure kinetics of C. glabrata biofilm formation, we quantified 137 
bioluminescence and cfu quantification after 90 min (adhesion period), 1, 2, 5 and 7 days. At 138 
each imaging time point, the BLI signal retrieved from reporter strain C. glabrata lucOPT 139 
7/2/4 cells was significantly higher compared to the signal emitted from the WT strain 140 
(Figure 2A, C). The number of fungal cells significantly increased between adhesion and the 141 
first 24 h of biofilm formation (Figure 2B). At later time points of biofilm formation, the BLI 142 
signal and the amount of cfu remained stable. In addition, we show that this reporter strain 143 
allows accurate in vitro biofilm quantification, as cfu and bioluminescence correlated well 144 
(Spearman r=0.7027, n=27, p<0.0001). Taken together, these results indicate that BLI 145 
represents a sensitive tool to study in vitro C. glabrata adherence and biofilm formation on 146 
abiotic surfaces.  147 
 148 
In vivo BLI of Candida glabrata biofilms developed in a subcutaneous mouse model  149 
Biofilm formation can impose serious medical problems in immunocompromised patients. 150 
First, we assessed the role of immunosuppression on C. glabrata biofilm and on 151 
dissemination into the surrounding tissue. One group of mice was treated with 152 
dexamethasone (0.4 mg/L) in the drinking water, whereas the second group remained 153 
immunocompetent. Our preliminary experiment displayed no major differences in the 154 
number of cfu after devices were explanted from immunocompromised and 155 
immunocompetent mice (Figure S2 A). Similarly, the number of C. glabrata cells quantified 156 
from tissue surrounding catheters was almost identical (Figure S2 B). As no significant 157 
difference was observed among both groups we continued our experiments in 158 
immunocompetent mice. Moreover, fungal cells did not disseminate into any vital organ of 159 
immunocompromised or immunocompetent mice as no cfu were retrieved from kidneys, liver 160 
nor spleen after homogenization (data not shown).  161 
In this model, catheters infected with C. glabrata WT cells and lucOPT 7/2/4 expressing strain 162 
were implanted subcutaneously on the left and right side, respectively of the lower back of 163 
mice (Figure 3A). In vivo imaging was performed after catheter implant and continued on 164 
day 1, 5 and 7 (Figure 3A). At every imaging time point 3 mice were sacrificed and explanted 165 
catheters were used for ex vivo quantification. A significant BLI signal was detected only 166 
from C. glabrata lucOPT 7/2/4 biofilm-forming cells, where it increased significantly over 167 
time (Figure 3A, B). The quantification of cfu documented with the BLI signal in parallel 168 
was significantly higher between adhesion (90 min) and 1st day of biofilm maturation (Figure 169 
3C). Moreover, the number of biofilm-forming cells and bioluminescent signal retrieved from 170 
C. glabrata lucOPT 7/2/4 correlated well (Spearman r=0.7576, n=10, p<0.0149) (Figure 3A, 171 
B). These findings indicate that BLI can be used for continuous detection and quantification 172 
of in vivo C. glabrata biofilm formation. 173 
 174 
In vivo BLI of fluconazole and caspofungin activity against C. glabrata biofilms  175 
Prior to in vivo experiments, we performed few tests to determine the efficacy of an azole 176 
fluconazole and an echinocandin caspofungin on free-living cells and in vitro biofilms. C. 177 
glabrata planktonic cells showed decreased susceptibility to fluconazole (MIC50 ranging 178 
from 8 - 16 µg/ml), whereas all strains were susceptible to caspofungin (0.0625 mg/L). In 179 
vitro C. glabrata biofilms did not respond to therapy with fluconazole (>64 mg/L), while 180 
caspofungin (0.25 mg/l - 0.5 mg/L) significantly decreased the number of C. glabrata 181 
biofilm-forming cells of all strains tested (Figure S3). Further, we evaluated the activity of 182 
fluconazole (125 mg/kg of body weight/day) and caspofungin (10 mg/kg of body weight/day) 183 
against in vivo C. glabrata biofilms. Daily in vivo imaging and the number of cfu retrieved 184 
from catheters ex vivo on day 9 revealed that fluconazole was not active against C. glabrata 185 
biofilm-forming cells (Figure 4A, B, C, D). In contrast, the signal detected in mice treated 186 
with caspofungin significantly decreased from day 4 of treatment until day 7 (Figure 4A, B). 187 
Furthermore, treatment with caspofungin resulted in significantly decreased number of cfu 188 
recovered from polyurethane devices ex vivo (Figure 4C, D). In conclusion, these data 189 
support the use of BLI to demonstrate activities of antifungal agents against biofilms under in 190 
vivo conditions.  191 
 192 
Discussion  193 
Usage of indwelling medical devices has become indispensable to medical care. 194 
Unfortunately, the increased risk of biofilm related infections in hospitalized patients is 195 
associated with the use of these devices.  One of the key challenges in biofilm research is the 196 
development of in vivo models that allow assessment of the efficacy of existing or novel 197 
therapeutics. So far, only a few in vitro C. glabrata biofilm model systems have been 198 
introduced to elucidate the different stages of biofilm, its architecture and response to 199 
antifungal treatment (2). However, these models do not take the host immune system and 200 
changes at the host site of infection into consideration, which are crucial during infections in 201 
humans. Up to date, in vivo C. glabrata biofilms have been studied inside central venous 202 
catheters as described by Nett et al. (14). Recently, in vivo C. glabrata biofilms have been 203 
established subcutaneously in immunocompromised Sprague Dawley rats (5). In this study 204 
we established an in vivo C. glabrata infection model that mimics non-bloodstream biofilm-205 
associated infections in immunocompetent mice. This model is of interest given the frequent 206 
development of such biofilms in endotracheal tubes, intracardiac prosthetics and prosthetic 207 
joints (15). Our flow cytometry experiments (data not shown) displayed a trend towards more 208 
neutrophil recruitment in the subcutaneous area surrounding catheter pieces 72 h post-surgery 209 
in animals carrying C. glabrata-infected catheters compared to non-infected devices. These 210 
findings suggest that the host immune system is triggered upon C. glabrata infection 211 
however that the predominant innate immune response is likely not driven solely by 212 
neutrophils. Further research elucidating the specific innate immune response towards these 213 
biofilms has to be conducted. Translation of the originally developed rat model to mice 214 
improved the cost-efficiency of in vivo experiments and presents potential to study biofilm 215 
formation in different transgenic mice allowing us to discover different host factors that may 216 
affect biofilm development. 217 
In the majority of animal experiments, the number of cfu’s is determined post-mortem which 218 
requires a large number of animals in order to perform time-course experiments. This is also 219 
the case if one wants to study the effect of antifungals on catheter-associated biofilm 220 
infections in animals. Because of this, we searched for an alternative tool which allowed us to 221 
study the development of infection repeatedly in the same animal. Bioluminescence imaging 222 
(BLI) has been previously described as a sensitive, reliable and non-invasive technique to 223 
follow systemic candidiasis caused by C. albicans and its dissemination into kidneys (10-12). 224 
Additionally, BLI has been applied to study subcutaneous C. albicans infections (10) and 225 
vulvovaginal candidiasis (11). It was used to monitor C. albicans biofilm formation in a 226 
subcutaneous catheter mouse model (13). In that particular scenario, Gaussia princeps 227 
luciferase was expressed on the cell wall (12) and emitted light upon contact with the 228 
substrate coelenterazine, whereby light emission correlated with cfu (13). Gabrielli et al. 229 
(16), used C. albicans strains with extracellularly expressed G. princeps luciferace to study 230 
development of oropharyngeal candidiasis. They found that in vivo BLI was more reliable 231 
than cfu counts detecting early infection in the oral cavity of the host. Very recently, red-232 
shifted firefly luciferase has been introduced to test the fate of C. albicans in different animal 233 
models (17). In our study, the use of firefly luciferase is known for its glow-type 234 
bioluminescence over a period of time and therefore, is advantageous in comparison with 235 
other reporter systems (18). Renilla luciferase and beetle reporter systems have been used to 236 
study eukaryotes. In the case of bacteria it is advantageous to use luminescent reporters based 237 
on the lux operon with intracellular expression of luciferase (6). Furthermore, the strains 238 
generated here are otherwise not auxotrophic and show no altered phenotype when compared 239 
to the parental WT. We have clearly demonstrated that BLI is sensitive and a powerful tool to 240 
study long-term infection development on abiotic surfaces within living animals.  241 
It is known that the extracellular matrix serves as a protective barrier allowing 242 
microorganisms to withstand high concentrations of antimicrobial agents. Treatment of C. 243 
glabrata can be especially challenging because of its acquired resistance to the “gold-244 
standard” antimycotic fluconazole (4). In our study, daily administration of fluconazole (125 245 
mg/kg of body weight/day) for 7 days did not cause any significant decline in the number of 246 
C. glabrata catheter-associated cells as comparable BLI and cfu. However, daily 247 
administration of caspofungin (10 mg/kg of body weight/day) significantly decreased the 248 
number of cfu retrieved from implanted catheters in comparison with saline-treated animals. 249 
Remarkably, daily monitoring of animals resulted in decreased signal from day 4 in 250 
caspofungin-treated animals. These studies are in agreement with our previous fluconazole 251 
and caspofungin efficacy testing in a rat model (5). Moreover,  we (19) displayed that 252 
fluconazole failed its efficacy on C. albicans biofilms, whereas caspofungin showed very 253 
good activity to treat device-associated infections in the subcutaneous mouse model.  254 
In conclusion, bioluminescence imaging is a reliable and non-invasive method not only to 255 
visualize but also to quantify fungal biofilms. Even more importantly, this technique is cost 256 
effective offering the capability to study the activity of novel or existing antimicrobial agents 257 
over the course of time avoiding animal sacrifice at each time point. The model presented in 258 
this study combined with BLI can be easily used by other researchers to exploit the role of 259 
the host immune system in infection when using different knockout mice, to study host-260 
pathogen interactions using different C. glabrata strains, as well as for rapid screening during 261 
early drug discovery. 262 
 263 
Materials and methods 264 
Ethics 265 
All animal experiments were performed in accordance with the KU Leuven animal care 266 
guidelines and were approved by the Ethical Committee of the KU Leuven (project number 267 
P090/2013). All animals were given a standard ad libitum diet and housed at random with 4 268 
animals in filter-top cages in a dedicated animal room where temperature, light and humidity 269 
was regulated. 270 
 271 
Generation of C. glabrata histidine auxotrophic mutants 272 
All oligonucleotides used in this study are described in Supplementary Table 1. For 273 
generation of a histidine auxotrophic mutant of C. glabrata ATCC2001 (WT) the HIS1 locus 274 
was selected for gene deletion. A 750 bp promoter region (P1 + P2) and a 693 bp 275 
downstream region (P3 + P4) of the HIS1 gene were amplified from C. glabrata genomic 276 
DNA. Oligonucleotides P1 and P4 contained overlapping sequences to the BamHI restricted 277 
pUC19 vector. Oligonucleotides P2 and P3 contained flanking sequences to the 278 
nourseothricin resistance cassette that was amplified with oligonucleotides P5 and P6 from 279 
plasmid pJK863 (20). Primer P5 contained an overlap to the upstream and P6 to the 280 
downstream flanking region of the HIS1 gene. PCR reactions were performed with Phusion 281 
Hot Start II polymerase (Thermo) and PCR fragments were gel purified using the GeneJet 282 
Gel purification kit (Thermo). All fragments were mixed with the BamHI restricted pUC19 283 
plasmid and assembled by in vitro recombination using the InFusion HD cloning kit 284 
(Takara/Clonetech). After transformation of E. coli DH5α cells, oligonucleotides P1 + P7 and 285 
P4 + P8 were used to screen colonies for correct plasmid assembly. Plasmid DNA was 286 
isolated, restricted with KpnI and used for electroporation of C. glabrata WT cells (21). 287 
Transformants were regenerated on YPD medium with 200 µg/mL nourseothricin. Individual 288 
colonies were tested for histidine auxotrophy. Integration of the deletion construct into the 289 
HIS1 locus was confirmed by diagnostic PCR with oligonucleotides P7 + P9. The deletion 290 
mutants '2/4 and '2/12 were used in downstream experiments for generation of 291 
bioluminescent strains. 292 
 293 
Generation and characterization of luciferase expressing C. glabrata strains 294 
A codon-optimized synthetic firefly luciferase gene adapted to the codon usage of C. 295 
glabrata was used for generation of bioluminescent C. glabrata strains. To ensure 296 
constitutive gene expression, the promoter of the enolase gene (pENO1) was selected. The 297 
enolase promoter was amplified with oligonucleotides P10 + P11 from genomic DNA of WT 298 
and ligated into the NdeI-site of the luciferase gene containing plasmid pUC57. The ENO1 299 
promoter in combination with the luciferase gene was amplified with oligonucleotides P12 + 300 
P13, whereby P12 contained an overhang to a short terminator region of the HIS1 gene and 301 
P13 an overhang to a downstream region of the HIS1 gene. To integrate the luciferase 302 
construct into the original HIS1 locus of the 'HIS1 strains, the HIS1 gene with 720 bp 303 
promoter region and a short 60 bp terminator sequence were amplified from genomic DNA 304 
of WT with oligonucleotides P14 + P15. Oligonucleotide P14 contained an overhang to the 305 
BamHI site of the pUC19 plasmid and P15 an overhang to the ENO1 promoter. Finally, to 306 
enable a homologous integration into the HIS1 locus, a 668 bp downstream region of the 307 
HIS1 gene was amplified from C. glabrata genomic DNA with oligonucleotides P16 and 308 
P17, whereby P16 overlapped with the 3’-end of the luciferase and P17 with the BamHI 309 
restricted puC19 vector. All PCR fragments were gel purified and mixed with the BamHI 310 
restricted puC19 vector for in vitro recombination using the InFusion HD cloning kit. E. coli 311 
DH5α was transformed with the reaction mixture and correct plasmids were identified by 312 
colony PCR using oligonucleotides P18 + P19 for the fusion of the luciferase cassette with 313 
the HIS1 gene and P20 +P21 for the combination of the luciferase gene with the HIS1 314 
downstream region. Correctly assembled plasmids were purified and the transformation 315 
cassette was excised from the pUC19 backbone by BamHI restriction and used for 316 
transformation of C. glabrata HIS1 deletion mutants using histidine prototrophy as selection 317 
marker. Transformants were regenerated on yeast nitrogen base (YNB) with ammonium but 318 
w/o amino acids and niacin as supplement. Transformants were pre-screened for loss of 319 
nourseothricin resistance, which was expected by homologous integration of the reporter 320 
cassette into the original HIS1 locus of HIS1 deletion mutants. Integration of the cassette into 321 
the correct locus was additionally confirmed by diagnostic PCR using oligonucleotides P9 + 322 
P22. Finally, transformants were streaked on YNB agar plates containing 0.4 mM D-luciferin 323 
and analyzed for bioluminescence using an IVIS 100 system (Perkin Elmer). Two 324 
independent transformants, namely C. glabrata lucOPT 7/2/4 and lucOPT 8/1/4 producing 325 
similar signal intensities were selected for further work. An overview of the strains used in 326 
this study is provided in Supplementary Table 2.  327 
All strains were grown on YPD (1% yeast extract, 2% peptone, 2% glucose) agar plates at 30 328 
°C. C. glabrata planktonic cultures were incubated in liquid YPD medium for 72 h at 30 °C 329 
(stationary phase). The growth of planktonic cells was followed by BioscreenC (Labsystems) 330 
at 30 °C and 37 °C under continuous shaking for 24 hours and measurements were taken 331 
every 30 min.  332 
 333 
In vivo C. glabrata biofilm formation in a murine subcutaneous biofilm model  334 
We translated a rat subcutaneous biofilm model (5) to specific pathogen-free 335 
immunocompetent BALB/c mice (6-8 weeks old, 20 g). C. glabrata (1×106 cells/mL) 336 
attached onto the surface of serum-coated polyurethane catheter pieces during in vitro 337 
adhesion (90 min, 37°C) followed by a washing step with PBS. Mice were anesthetized as 338 
previously described (5). In order to compare bioluminescence from the WT control strain 339 
and the bioluminescent strain in a single animal, two small incisions were made, one on the 340 
left and one on the right side of the back of a mouse, as previously demonstrated (22). Three 341 
catheter pieces seeded with WT were implanted on the left and 3 catheters infected with 342 
bioluminescent strain were inserted on the right side of the back. For catheter explant, 343 
animals were sacrificed by cervical dislocation. Catheter fragments were removed, washed 344 
twice with PBS and placed to microcentrifuge tubes containing PBS. Devices were sonicated, 345 
vigorously vortexed and plated to enumerate the number of colony-forming units (cfu). 346 
Dissemination of C. glabrata cells from biofilms into the kidneys, liver, spleen and the tissue 347 
surrounding the catheter pieces was examined after 48 and 144 h of biofilm formation.  348 
 349 
In vivo BLI 350 
Isoflurane anesthesia and the BLI procedure were performed as described before (13, 22). 351 
Prior to BLI, fresh D-luciferin solution (33.3 mg/mL) was dissolved in sterile saline (0.9 % 352 
NaCl). A photograph was taken to ensure that the animals are in the desired position for 353 
imaging. Subsequently, 100 μL of the D-luciferin substrate was injected subcutaneously at 354 
both sides of the back, at the regions surrounding the implanted catheter pieces. During 355 
substrate injection, animals were kept anaesthetized through a nose cone providing gas 356 
anesthesia. Consecutive series of scans were acquired at 60 s exposure time (medium 357 
binning) until the maximum signal was reached (around 15 min after injection). Rectangular 358 
region of interests (ROIs) were drawn around each trio of catheters and reported as photon 359 
flux per second (p s−1). Background BLI signal was measured by using the same ROI after 360 
injecting D-luciferin subcutaneously on the upper back of the mouse where no catheters were 361 
implanted.  362 
 363 
In vivo antifungal treatment  364 
Stock solution of fluconazole (Sigma Aldrich, USA) was dissolved in sterile water, whereas 365 
caspofungin was prepared in pure DMSO. Intraperitoneal administration of fluconazole (125 366 
mg/kg of body weight/day) and caspofungin (10 mg/kg of body weight/day) was initiated 24 367 
h post implant. Solutions for injection were prepared in sterile saline and administered 368 
intraperitoneally once daily for 7 days. In case of caspofungin the concentration of DMSO 369 
used for the injection was 0.5%. Control group of mice was injected with sterile saline. 370 
 371 
Additional materials and methods are described in Supplementary file.  372 
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 451 
  452 
Figure legends: 453 
Figure 1. In vitro BLI of Candida glabrata biofilm formation on 96 well plate and inside 454 
polyurethane catheters  455 
(A) Bioluminescence signal intensity and (B) XTT data measurements were obtained after 456 
adherence (90 min, black columns, n = 18 wells or devices per strain) and biofilm formation 457 
(48 h, white columns, n = 18 wells or catheters per strain) by C. glabrata ATCC 2001 (WT), 458 
C. glabrata lucOPT 7/2/4 and lucOPT 8/1/4 in 96-well plate. (C) A characteristic 459 
bioluminescent image of 2 days-old biofilm formed on the surface of a 96-well plate. (D) 460 
Measurements of BLI signal and (E) colony forming unit counts (cfu) from C. glabrata 461 
adhered cells (90 min, black columns) and biofilms formed (48 h, white columns) inside 462 
catheters. (F) A typical picture of BLI acquired after 2 days of biofilm formation inside 463 
polyurethane fragments. Statistical analyses were performed using Two-way ANOVA with 464 
post-hoc Tukey HSD test. Differences were considered significant at *p ≤ 0.05. Error bars 465 
indicate SD of replicate samples.  466 
 467 
Figure 2. In vitro BLI of Candida glabrata ATCC 2001 (WT) and C. glabrata lucOPT 468 
7/2/4 biofilm formation inside polyurethane catheters over time  469 
(A) Bioluminescent signal intensity acquired at different time points (adhesion, 1, 2, 5 and 7 470 
days) of C. glabrata ATCC 2001 (WT, black columns) and C. glabrata lucOPT 7/2/4 (white 471 
columns) biofilm development inside catheters. (B) BLI was accompanied with colony 472 
forming unit counts (cfu) after adherence and 1, 2, 5 and 7 days of in vitro biofilm formation 473 
inside polyurethane devices (n = 18 devices per strain and time point). (C) A BLI signal 474 
retrieved after adhesion (90 min) and later stages of biofilm formation. Two-way ANOVA 475 
with post-hoc Tukey HSD test was used to perform statistical analyses. Differences were 476 
considered significant at *p≤0.05 and error bars indicate SD of replicate samples.  477 
 478 
Figure 3. In vivo Candida glabrata ATCC 2001 (WT) and Candida glabrata lucOPT 7/2/4 479 
biofilm formation studied by longitudinal BLI  480 
(A) In vivo BLI of C. glabrata biofilm formation after implant (90 min, period of adhesion) 481 
and 1, 5 and 7 days of biofilm formation. Three polyurethane devices infected with C. 482 
glabrata ATCC2001 (WT) strain were implanted on left side of the back, whereas 3 devices 483 
challenged with lucOPT 7/2/4 were inserted on the ride side of the back of the animal.  (B) 484 
Quantification of bioluminescence signal intensity acquired at different time points 485 
(adhesion, 1, 5 and 7 days, n=6 animals per time point, except for a group with non-infected 486 
catheters with n=1) of non-infected devices (black columns), C. glabrata ATCC 2001 (grey 487 
columns) and C. glabrata lucOPT 7/2/4 (white columns) biofilm formation.  (C) Colony 488 
forming unit counts (cfu) retrieved from catheters infected with C. glabrata ATCC2001 489 
(black columns) and with C. glabrata lucOPT 7/2/4 (white columns) after adhesion and 1, 5 490 
and 7 days of in vitro biofilm formation inside polyurethane devices. (C) A BLI signal 491 
intensity retrieved after adhesion (90 min) and later stages of biofilm formation. Statistical 492 
analyses were performed using Two-way ANOVA with post-hoc Tukey HSD test. 493 
Differences were considered significant at *p≤0.05 and error bars indicate SD of replicate 494 
samples.  495 
 496 
Figure 4. BLI of fluconazole (FLC) and caspofungin (CAS) efficacy against in vivo 497 
Candida glabrata ATCC 2001 (WT) and Candida glabrata lucOPT 7/2/4 biofilm-498 
associated infections 499 
(A) Representative images of a signal acquired from Candida glabrata ATCC 2001 (WT, 3 500 
devices implanted on the left side of the back of mice) and C. glabrata lucOPT 7/2/4 (3 501 
catheters inserted on the right side of the back of a host) biofilms. Biofilms were formed for 502 
24 h and afterwards treatment with fluconazole (125 mg/kg of body weight/day, n=4) and 503 
caspofungin (10 mg/kg of body weight/day, n=4) was initiated. Drugs were administered 504 
once daily for 7 days. Control-treated group of animals (n=4) was injected with sterile saline. 505 
(B) Quantification of BLI signal intensity, which started to decrease 4 days after animal 506 
treatment with caspofungin. Data show an average ± SEM of a BLI signal acquired from 507 
catheters implanted in animals treated with fluconazole or caspofungin on different days. (C) 508 
C. glabrata ATCC 2001 and (D) C. glabrata lucOPT 7/2/4 colony forming unit (cfu) counts 509 
retrieved from individual catheters after biofilm formation. Each symbol represents the 510 
Log10 colony forming units (cfu) ± SEM of saline-treated (control) and treated fungal cells 511 
retrieved from catheter pieces from individual mice. The bar represents the average Log10 512 
cfu ± SEM of the number of fungal cells retrieved from a drug-free and from a treated group 513 
of animals. Two-way ANOVA with post-hoc Tukey HSD test was used to calculate statistical 514 
significance, when *p≤0.05.  515 




